Vertex Pharmaceuticals Inc (VRTX.OQ)

VRTX.OQ on NASDAQ Stock Exchange Global Select Market

122.65USD
11:11am EDT
Change (% chg)

$0.50 (+0.41%)
Prev Close
$122.15
Open
$123.84
Day's High
$125.15
Day's Low
$122.38
Volume
139,174
Avg. Vol
582,335
52-wk High
$137.50
52-wk Low
$62.43

VRTX.OQ

Chart for VRTX.OQ

About

Vertex Pharmaceuticals Incorporated engages in the discovery, development, manufacture, and commercialization of small molecule drugs for patients with serious diseases in specialty markets. The Company markets KALYDECO in the United States and international markets for the treatment of patients six years of age and older with... (more)

Overall

Beta: 0.35
Market Cap(Mil.): $29,960.92
Shares Outstanding(Mil.): 242.09
Dividend: --
Yield (%): --

Financials

  VRTX.OQ Industry Sector
P/E (TTM): -- 39.17 40.23
EPS (TTM): -3.12 -- --
ROI: -38.37 15.86 15.26
ROE: -60.68 16.36 16.08
Search Stocks

Tiny Corbus looks to take on Vertex with experimental lung drug

- Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco.

04 May 2015

Tiny Corbus looks to take on Vertex with experimental lung drug

May 4 - Corbus Pharmaceuticals Holdings Inc's experimental drug for cystic fibrosis, a rare lung-scarring disease, could be a real money spinner and pose a challenge to rival Vertex Pharmaceuticals Inc's successful treatment, Kalydeco.

04 May 2015

Fitch Affirms RPI Finance Trust's IDR at 'BBB-'; Outlook Stable

(The following statement was released by the rating agency) CHICAGO, November 21 (Fitch) Fitch Ratings has affirmed the ratings of RPI Finance Trust (RPI FT), including the 'BBB-' Issuer Default Rating (IDR), following the acquisition of royalty-bearing assets linked to Vertex Pharmaceutical Inc.'s (Vertex) cystic fibrosis treatment Kalydeco. The rating action applies to approximately $3.3 billion of debt outstanding as of Sept. 30, 2014. The Rating Outlook is Stable. A full list of rating

21 Nov 2014

Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 billion

- Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash.

19 Nov 2014

UPDATE 1-Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 bln

Nov 19 - Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash.

19 Nov 2014

Royalty Pharma buys royalties on Vertex Pharma drugs for $3.3 bln

Nov 19 - Pharmaceutical investment firm Royalty Pharma said it would buy royalties on Vertex Pharmaceuticals Inc's cystic fibrosis treatments from Cystic Fibrosis Foundation for $3.3 billion in cash.

19 Nov 2014

Competitors

  Price Chg
Johnson & Johnson (JNJ.N) $99.00 -0.50
Pfizer Inc. (PFE.N) $33.58 -0.26
Novartis AG (NOVN.VX) CHF93.75 -1.00
Merck & Co., Inc. (MRK.N) $60.49 -0.00
Roche Holding Ltd. (ROG.VX) CHF262.60 -4.50
Sanofi SA (SASY.PA) €90.62 +0.58
GlaxoSmithKline plc (GSK.L) 1,520.88p +20.00
AbbVie Inc (ABBV.N) $63.62 -0.24
Bristol-Myers Squibb Co (BMY.N) $64.93 -0.10
Bristol-Myers Squibb Co (BMYMP.PK) $1,090.24 --

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Stock Traders Daily
$20.00
Provider: New Constructs, LLC
$25.00
Provider: Thomson Reuters Stock Report
$25.00
Provider: Sadif Analytics Prime
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks